US EPA

7426992 

Journal Article 

Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation 

Yamazaki, DASDAS; Rozada, AMF; Baréa, P; Reis, EC; Basso, EA; Sarragiotto, MHMH; Seixas, FAV; Gauze, GF; , 

2021 

Yes 

Bioorganic & Medicinal Chemistry
ISSN: 0968-0896
EISSN: 1464-3391 

PERGAMON-ELSEVIER SCIENCE LTD 

OXFORD 

32 

115991 

English 

33440318 

10.1016/j.bmc.2020.115991 

WOS:000616056900004 

https://linkinghub.elsevier.com/retrieve/pii/S096808962030821X
Exit
 

A novel series of arylcarbamate-N-acylhydrazones derivatives have been designed and synthesized as potential anti-cholinesterase agents. In vitro studies revealed that these compounds demonstrated selective for butyrylcholinesterase (BuChE) with potent inhibitory activity. The compounds 10a-d, 12b and 12d were the most potent BuChE inhibitors with IC50 values of 0.07-2.07 µM, highlighting the compound 10c (IC50 = 0.07 µM) which showed inhibitory activity 50 times greater than the reference drug donepezil (IC50 = 3.54 µM). The activity data indicates that the position of the carbamate group in the aromatic ring has a greater influence on the inhibitory activity of the derivatives. The enzyme kinetics studies indicate that the compound 10c has a non-competitive inhibition against BuChE with Ki value of 0.097 mM. Molecular modeling studies corroborated the in vitro inhibitory mode of interaction and show that compound 10c is stabilized into hBuChE by strong hydrogen bond interaction with Tyr128, π-π stacking interaction with Trp82 and CH⋯O interactions with His438, Gly121 and Glu197. Based on these data, compound10cwas identified as low-cost promising candidate for a drug prototype for AD treatment. 

Butyrylcholinesterase inhibitors; Carbamates; Molecular modeling; N-acylhydrazones